Evidence map›Paper›PMID 28143417›Full record

ArticleBMC infectious diseases2017

Early rising asexual parasitaemia in Nigerian children following a first dose of artemisinin-based combination treatments of falciparum malaria.

Akintunde Sowunmi, Kazeem Akano, Adejumoke I Ayede, Elsie O Adewoye, Godwin Ntadom, Bayo Fatunmbi, Grace O Gbotosho, Onikepe A Folarin, Christian T Happi

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Akintunde SowunmiDepartment of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria. akinsowunmi@hotmail.com.
Kazeem AkanoDepartment of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria.
Adejumoke I AyedeDepartment of Paediatrics, University of Ibadan, Ibadan, Nigeria.
Elsie O AdewoyeDepartment of Physiology, University of Ibadan, Ibadan, Nigeria.
Godwin NtadomNational Malaria Elimination Programme, Federal Ministry of Health, Abuja, Nigeria.
Bayo FatunmbiWorld Health Organization, Regional Office for the Western Pacific, Phnom Penh, Cambodia.
Grace O GbotoshoDepartment of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria.
Onikepe A FolarinDepartment of Biological Sciences, Redeemer's University, Ede, Nigeria.
Christian T HappiDepartment of Biological Sciences, Redeemer's University, Ede, Nigeria.
University of Ibadan · NGRedeemer's University · NGFederal Ministry of Health · NGUniversity College Hospital, Ibadan · NG

Funding

Host and Microbial Genetic Determinants of Febrile Illness in West AfricaU01HG007480 · NHGRI · REDEEMER'S UNIVERSITY · PI HAPPI, CHRISTIAN T. · 2013 to 2016
$1.6M
NHGRI NIH HHS U01 HG007480World Health Organization 001
6 · The paper itself

Abstract

backgroundEarly rising asexual parasitaemia (ERAP), initially defined as 'an increase in the parasite count over the baseline pre-treatment level during the first 24 h of treatment' of falciparum malaria with artemisinin derivatives is well documented, but there is no characterization of its risk factors, kinetics, molecular features or relationship to late-appearing anaemia (LAA) in acute falciparum malaria in African children following oral artemisinin-based combination therapies (ACTs).

methodsERAP was defined as ≥5% increase in pre-treatment parasitaemia within 8 h of initiating treatment. Parasitaemia was quantified pre-treatment and 1-2 hourly for 8 h, and less frequently thereafter for 6 weeks following randomized treatment of acutely malarious children with artesunate-amodiaquine, artemether-lumefantrine or dihydroartemisinin-piperaquine. Risk factors were determined by stepwise multiple logistic regression model. Kinetics of release into and of elimination of asexual parasites and DNA clones from peripheral blood were evaluated by method of residuals and non-compartment model, respectively. Parasite population changes were evaluated morphologically and by molecular genotyping.

resultsERAP occurred in 205 of 416 children. A parasitaemia <100,000/μL and parasitaemia 1 day post-treatment initiation were independent predictors of ERAP. In children with ERAP: mean and peak time of increase in parasitaemia were 105.6% (95% CI 81-130.1) and 2.5 h (95% CI 2.2-2.7), respectively. Mean lag time, half-time and rate constant of release were 0.2 h (95% CI 0.2-0.3), 1 h (95% CI 0.9-1.1), and 0.9 h

conclusionERAP is common, occurs rapidly as first order process and may be due to mobilization of parasites from deep tissue following a first dose of ACTs of acute childhood falciparum malaria. TRIALS REGISTRATION: Pan African Clinical Trial Registry PACTR201508001188143 , 3 July 2015; PACTR201510001189370, 3 July 2015; PACTR201508001191898, 7 July 2015 and PACTR201508001193368, 8 July 2015.

Indexed as

Administration, OralAdolescentAmodiaquineAntimalarialsArtemisininsChildChild Health ServicesChild, PreschoolDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantMalaria, FalciparumMaleAmodiaquineamodiaquine, artesunate drug combinationAntimalarialsArtemisininsDrug CombinationsArtemisinin-based combination treatmentsChildrenEarly rising asexual parasitaemiaNigeria

Identifiers

PMID28143417
PMCPMC5286790
OpenAlexW2584896442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.